or Try an Advanced Search...

    ETF Components for CNCR - Loncar Cancer Immunotherapy ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    GERN B 2.29 2.62
    ACRV B -3.26 2.52
    ELVN B 0.69 2.30
    JANX B -3.15 1.83
    NUVB B -0.75 1.75
    TSVT F -7.78 1.68
    PRLD C 0.00 1.68
    RVMD B -1.85 1.48
    NRIX B -2.69 1.47
    ITOS F -3.82 1.46
    LYEL C -5.74 1.45
    GLUE F -1.26 1.44
    ACET F -10.71 1.43
    FHTX F 0.97 1.41
    HCM A 0.88 1.40
    MGNX D -3.27 1.40
    MRK A 0.09 1.39
    STRO F -6.72 1.37
    AURA F -1.66 1.35
    RAPT F -1.25 1.35
    EXEL A 1.80 1.34
    MOR A 0.06 1.34
    SDGR F -3.10 1.32
    INBX D 0.73 1.32
    YMAB C -0.33 1.32
    GMAB F -0.32 1.30
    VOR F -7.45 1.30
    DAWN C -8.71 1.30
    CGEM B 13.32 1.30
    PGEN C 1.43 1.30
    BPMC B -0.03 1.29
    IPHA D 3.80 1.28
    ERAS F -2.59 1.28
    BCYC C -0.04 1.27
    SNDX D -0.86 1.27
    BNTX F -0.45 1.26
    REGN C -0.09 1.25
    DCPH D -0.34 1.25
    ZNTL F -6.36 1.25
    IGMS F 3.38 1.23
    IMCR D 2.02 1.23
    BMY F -0.27 1.23
    MRUS C 2.82 1.23
    IDYA D 2.13 1.23
    XNCR F 3.54 1.22
    DNA F -2.84 1.19
    RCUS F -0.45 1.18
    KYMR C -1.40 1.16
    KPTI F 0.00 1.15
    KURA C 0.11 1.15
    IMTX F -2.59 1.15
    SWTX C -1.41 1.14
    AUTL F -6.03 1.14
    TYRA C -2.32 1.11
    RLAY F 7.63 1.11
    IOVA D -1.26 1.11
    ACLX D -2.98 1.09
    REPL F -1.40 1.07
    ALLO F -9.79 1.05
    FATE D -5.29 1.04
    LEGN F -4.81 1.04
    NUVL C -0.59 1.03
    ARVN D -4.29 1.03
    SMMT D -3.75 1.02
    MRSN D -10.28 1.01
    CRBU F -3.27 1.01
    BMEA F -1.91 0.99
    RXRX F 3.12 0.96
    IMRX F -7.98 0.88
    RPTX F -1.79 0.88
    GNLX F -0.86 0.81

    Represented by ETF Holdings

    Keywords: Cancer Biopharmaceutical Medicine Biotechnology Clinical Medicine Life Sciences Immunology Solid Tumors Antibodies Immune System Biology Cancer Treatment Tyrosine Kinase Receptors Drug Discovery Treatment Of Cancer Monoclonal Antibodies Oncology Tumor Disease Protein Kinase Inhibitor
    Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Health Information Services Long-Term Care Facilities

    Recent News for Loncar Cancer Immunotherapy ETF & its Holdings

    Date Stock Title
    Apr 24 MRK Alphabet, Microsoft, Southwest earnings: What to watch
    Apr 24 SMMT Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
    Apr 24 ARVN Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
    Apr 24 CGEM Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
    Apr 24 ERAS Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
    Apr 24 ACRV Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
    Apr 24 KPTI Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
    Apr 24 IOVA Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
    Apr 24 RCUS Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
    Apr 24 REGN Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
    Apr 24 DAWN Day One slips despite Ojemda approval as BofA says label “not a home run”
    Apr 24 MRSN Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Apr 24 SWTX SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    Apr 24 BMY Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
    Apr 24 DAWN Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
    Apr 24 MOR MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
    Apr 24 PGEN Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
    Apr 24 MRK 4 Large Drug Stocks to Hold on to Amid Industry Challenges
    Apr 24 CGEM Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
    Apr 24 REGN Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
    ETF Series Solutions - Loncar Cancer Immunotherapy ETF is an exchange traded fund launched by ETF Series Solutions. The fund is co-managed by Exchange Traded Concepts, LLC and Vident Investment Advisory, LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating in the pharmaceutical or biotechnology sectors, including those companies identified as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. It invests in stocks of companies across all market capitalizations. The fund seeks to replicate the performance of the Loncar Cancer Immunotherapy Index, by investing in stocks of companies as per their weightings in the index. ETF Series Solutions - Loncar Cancer Immunotherapy ETF is domiciled in the United States.
    Exchange Traded Fund ETF Exchange Traded Funds Biotechnology SPDR Cancer Betashares Immune System Immunotherapy Cancer Immunotherapy Biotechnology Sectors Lonca
    Back to the Main CNCR Page...